Research progress of ERCC1 in non-small cell lung cancer based on the platinum drugs

Abstract

LIU Zhi-Bao, ZHANG Jing-Hua. Research progress of ERCC1 in non-small cell lung cancer based on the platinum drugs[J]. Journal of International Oncology, 2014, 41(12): 909-912.

［1］ Pignon J, Tribodet H, Scagliotti G, et al. Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Group［J］. J Clin Oncol, 2008, 26(21): 35523559. ［2］ Bepler G, Olaussen K, Vataire A, et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis［J］. Am J Pathol, 2011, 178(1): 6978. ［3］ De Dosso S, Zanellato E, Nucifora M, et al. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatinbased chemotherapy［J］. Cancer Chemother Pharmacol, 2013, 72(1):159165. ［4］ Li Y, Yang SY, Kang S, et al. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy［J］. Pharmacogenomics, 2012, 13(4): 419427. ［5］ Li P, Fang YJ, Li F, et al. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage Ⅲ colon cancer patients receiving oxaliplatinbased adjuvant chemotherapy［J］. Br J Cancer, 2013, 108(6): 12381244. ［6］ Gerhard R, Carvalho A, Carneiro V，et al. Clinicopathological significance of ERCC1 expression in breast cancer［J］. Pathol Res Pract, 2013, 209(6): 331336. ［7］ Krawczyk P, WojasKrawczyk K, Mlak R, et al. Predictive value of ERCC1 singlenucleotide polymorphism in patients receiving platinumbased chemotherapy for locallyadvanced and advanced nonsmall cell lung cancer—a pilot study［J］. Folia Histochem Cytobiol, 2012, 50(1): 8086. ［8］ Roth JA ,Carlson JJ. Prognostic role of ERCC1 in advanced nonsmallcell lung cancer: a systematic review and metaanalysis［J］. Clin Lung Cancer, 2011, 12(6): 393401. ［9］ Hubner RA, Riley RD, Billingham L, et al. Excision repair crosscomplementation group 1 (ERCC1) status and lung cancer outcomes: a metaanalysis of published studies and Recommendations［J］. PLoS One, 2011, 6(10): e25164. ［10］ Gregg SQ，Robinson AR，Niedernhofer LJ．Physiological consequences of defects in ERCC1XPF DNA repair endonuclease［J］．DNA Repair(Amst), 2011, 10(7): 781791．［11］ Orelli B, Mcclendon T, Tsodikov O, et al. The XPAbinding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways［J］. J Biol Chem, 2010, 285(6): 37053712. ［12］ Li J, Li Z, Yu LC, et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced nonsmall cell lung cancer who received neoadjuvant chemotherapy［J］. Lung Cancer, 2010, 69(1): 116122. ［13］ TsedenIsh M, Choi YD, Cho HJ, et al. Diseasefree survival of patients after surgical resection of nonsmall cell lung carcinoma and correlation with excision repair crosscomplementation group 1 expression and genotype［J］. Respirology, 2012, 17(1): 127133. ［14］ Leng XF, Chen MW, Xian L, et al. Combined analysis of mRNA expression of ERCC1, BAG1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with nonsmall cell lung cancer who received adjuvant chemotherapy［J］. J Exp Clin Cancer Res, 2012, 31(25): 157162. ［15］ Wang X， Zhao J， Yang L， et al． Positive expression of ERCC1 predicts a poorer platinumbased treatment outcome in Chinese patient with advanced nonsmall cell lung cancer［J］．Med Oncol， 2010, 27(2): 484490．［16］ Yan D, Wei P, An G,et al.Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage Ⅲ（N2） nonsmall cell lung cancer［J］. J Cardiothorac Surg, 2013, 8(1): 149153. ［17］ Zhang S, Li Q, Zhang Q, et al. Expression of ERCC1 and class Ⅲ βtubulin in resected nonsmall cell lung cancer and its correlation with platinumbased adjuvant chemotherapy［J］. Int J Biol Markers, 2010, 25(3): 141149. ［18］ Usanova S, PiéeStaffa A, Sied U, et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrandcrosslink repair and low ERCC1XPF expression［J］. Mol Cancer, 2010, 9(3): 248260. ［19］ Ma D, Baruch D, Shu Y, et al. Using protein microarray technology to screen antiERCC1 monoclonal antibodies for specificity and applications in pathology［J］. BMC Biotechnol, 2012, 12(1): 88. ［20］ Jiang J, Liang X, Zhou X, et al. ERCC1 expression as a prognostic and predictive factor in patients with nonsmall cell lung cancer: a metaanalysis［J］. Mol Biol Rep, 2012, 39(6): 69336942. ［21］ Seyhan EC, Altin S, Cetinkaya E, et al. Prognostic significance of ERCC1 expression in resected nonsmall cell lung carcinoma［J］. Ann Thorac Cardiovasc Surg, 2011, 17(2): 110117. ［22］ Zhu XD, Niedernhofer L, Kuster B, et al. ERCC1/XPF removes the 3′overhang from uncapped telomeres and represses formation of telomeric DNAcontaining double minute chromosomes［J］. Mol Cell, 2003, 12(6): 14891498.

[1]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui.Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway[J]. Journal of International Oncology, 2023, 50(7): 398-406.
[3]	Fan Yangyang, Wang Ying, Yuan Feng, Du Shanping, He Rongrong, Jia Yan.Study on the mechanism of MALAT1 targeting miR-142-3p in ovarian cancer chemotherapy resistance[J]. Journal of International Oncology, 2020, 47(2): 82-89.
[4]	Zhang Dongwei, Lan Bing.Effects of different chemotherapies on prognosis and tumor markers in patients with small cell lung cancer[J]. Journal of International Oncology, 2019, 46(10): 585-589.
[5]	Qiao Yunfeng, Li Ping, Fu Zhenming.Clinical application of cisplatin and nedaplatin[J]. Journal of International Oncology, 2018, 45(8): 561-565.
[6]	Li Yan.Effect of resveratrol on cisplatin chemotherapy sensitivity of ovarian cancer cells[J]. Journal of International Oncology, 2018, 45(1): 5-.
[7]	Hou Yuxiao, Sheng Lijun, Zhao Chunhong, Zhang Zhen, He Weina.Effect of a novel oncolytic herpes simplex virus type Ⅱ on lung adenocarcinoma[J]. Journal of International Oncology, 2017, 44(4): 266-270.
[8]	Wang Wei, Ren Biyong.Efficacy of recombinant human endostatin combined with TP regimen on patients with advanced EGFR wild type squamous cell lung carcinoma[J]. Journal of International Oncology, 2017, 44(10): 745-748.
[9]	An Cheng, Zhang Huanjiang.Phase Ⅱ clinical study of paclitaxel and cisplatin combined with concurrent radiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2017, 44(10): 736-739.
[10]	Zhang Jing, Chen Qun, Ke Mingyao, Zhuang Xibin, Shi Qin, Yong Yazhi, Huang Cheng.Randomized controlled clinical trial of nedaplatin combined with gemcitabine and cisplatin combined with gemcitabine in the treatment of advanced lung squamous cell carcinoma[J]. Journal of International Oncology, 2017, 44(1): 15-18.
[11]	LIU Dong-Ju, ZHAO Qiu-Sheng, YAO Yu.Effects of curcumin combined with cisplatin on growth and lymphatic metastasis of cervical cancer xenografts in nude mice[J]. Journal of International Oncology, 2016, 43(4): 241-245.
[12]	ZHU Yan-Zhe, SUN Guo-Ping.Efficacy and safety of recombinant human Adp53 injection combined with cisplatin in treating malignant pleural effusion: a Metaanalysis[J]. Journal of International Oncology, 2015, 42(5): 336-341.
[13]	LIU Na, CHENG Jun, MENG Ling-Zhan, LIU Yong.Paclitaxel liposome combined with cisplatin chemotherapy in nonsmall cell lung cancer with brain metastasis[J]. Journal of International Oncology, 2015, 42(5): 321-323.
[14]	YUE Li-Juan, HOU Xin-Li, XUE Hui, XUE Ling, GAO Xiang, SHEN Yong, YUAN Liang, ZHANG Jing-Jing, ZHU Hong-Cai.Pemetrexed in combination with cisplatin in the treatment of advanced breast cancer application[J]. Journal of International Oncology, 2014, 41(7): 545-548.
[15]	ZHONG Zhao-Kun, WANG Ping, ZHANG Yao, et al.Clinical investigation of isosorbide mononitrate plus vinorelbine and cisplatin in patients with previously untreated advanced stage non–small-cell lung cancer[J]. Journal of International Oncology, 2013, 40(8): 625-629.

Research progress of ERCC1 in non-small cell lung cancer based on the platinum drugs

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments